HCV: Continuing Advances From Individual Cure to Disease Elimination
Source: HCV: Continuing Advances From Individual Cure to Disease Elimination

Table of Contents

 

Video Module

Led by Norah Terrault, MD, MPH, a panel of experts including Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; and Ira M. Jacobson, MD, provides an overview of the current state of HCV therapy, emphasizing the unprecedented levels of efficacy and simplicity in curing individual patients, and discusses important strategies for eliminating HCV infection across communities and ultimately throughout the world.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate state-of-the-art regimens to cure HCV among patients currently engaged in care
  • Accelerate the uptake of HCV screening, diagnosis, and referral for treatment in primary care settings
  • Implement strategies to overcome barriers to successful HCV management in diverse patient populations
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Norah Terrault
    MD, MPH

Faculty

  • Gregory Dore
    MBBS, PhD, FRACP, MPH
    Graham R. Foster
    FRCP, PhD
    Ira M. Jacobson
    MD

Credit Information

  • Release Date:
    December 19, 2016
  • Expiration Date:
    December 18, 2017
  • Physicians:
    maximum of 1.75 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.7 Nursing contact hours

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Biotest, Cocrystal Pharma, Echosens North America, Gilead Sciences, and Merck and funds for research support from AbbVie, Biotest, Bristol-Myers Squibb, Gilead Sciences, and Merck.

 

Faculty

Gregory Dore, MBBS, PhD, FRACP, MPH


Professor, Head
Viral Hepatitis Clinical Research Program
Kirby Institute
University of New South Wales
Professor
Infectious Diseases Physician
St Vincent's Hospital
Sydney, Australia

Gregory Dore, MBBS, PhD, FRACP, MPH, has disclosed that he has received consulting fees, fees for non-CME/CE services, and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.
 

Graham R. Foster, FRCP, PhD


Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Janssen, and Merck; has received fees for non-CME/CE services and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck; and has ownership interest in GlaxoSmithKline.
 

Ira M. Jacobson, MD


Chair, Department of Medicine
Mount Sinai Beth Israel
Professor of Medicine and Vice-Chair, Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received consultant/advisor fees from AbbVie, Achillion, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Trek; has served on speaker bureaus for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Janssen; and has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, and Merck.
 

Staff

Rachael M. Andrie, PhD


Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
 

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians, registered nurses, and other healthcare professionals involved in the care of patients infected with HCV.


Goal

The goal of this activity is to enable participants to cure HCV in individual patients and to contribute to efforts to eventually achieve HCV elimination.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate state-of-the-art regimens to cure HCV among patients currently engaged in care
  • Accelerate the uptake of HCV screening, diagnosis, and referral for treatment in primary care settings
  • Implement strategies to overcome barriers to successful HCV management in diverse patient populations
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Credit Designation

This educational activity for 1.7 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

 

Commercial Support


This program is supported by an educational grant from Gilead Sciences.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 19, 2016, through December 18, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.